Loncastuximab Tesirine Combo Is Effective, Safe in R/R Follicular Lymphoma
Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Cilta-cel Shows High Responses for Lenalidomide-Refractory Myeloma in First Relapse
The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Eftilagimod Alpha/Pembrolizumab Elicits Encouraging Responses in HNSCC
The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.
European Commission Approves Enzalutamide in nmHSPC Subset
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.